Eli Lilly and Company Products - Search News

Hosted on MSN · 1d

Eli Lilly stock down on Q4 guidance miss

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue guidance down 5%,

Business Insider · 17h

TD Cowen Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00. The

Zacks.com on MSN · 1d

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

YAHOO!Finance · 1d

Has Eli Lilly Stock Peaked?

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first healthcare company to top a $1 trillion valuation,

24/7 Wall St · 21h

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 465.16% and currently trading at $747.20. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,

Zacks.com on MSN22h

Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip

Eli Lilly slashes the revenue guidance for the fourth quarter and fiscal 2024 but offers a bullish outlook for 2025.

1d

Eli Lilly & Co: Strong Growth Prospects and Strategic Positioning Justify Buy Rating

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

1don MSN

S&P 500 Gains and Losses Today: Eli Lilly Stock Falls as Sales Outlook Weakens

The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead of Wednesday's ...

GlobalData on MSN1d

JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400m

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

5d

Eli Lilly: Still Much Room To Ride The Weight-Loss Wave

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

1d

Eli Lilly & Co: Strong Growth Prospects and Strategic Investments Justify Buy Rating

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geoff Meacham ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results